经导管主动脉瓣置换术后可能瓣叶血栓的发生率、预测因素与中期结局
单中心注册研究纳入70例植入Edwards SAPIEN-XT装置的患者,采用多排CT随访发现瓣叶低密度增厚(HALT)累积发生率在出院时1.4%、6个月10.0%、1年14.3%。HALT与男性、较大主动脉窦及较大生物瓣尺寸相关,随访期D-二聚体升高,但未额外抗凝情况下瓣膜血流动力学及中期临床结局未见异常。
要点
- TAVR术后多排CT可见瓣叶低密度增厚(HALT),1年累积发生率14.3%,多无明显临床症状。
- HALT组男性比例70% vs 非HALT组25%,主动脉窦较大(31.0±2.0 mm vs 28.6±2.6 mm)。
- 26 mm生物瓣HALT发生率33.3%(7/21),高于23 mm瓣的6.1%(3/49)。
核心结论
- 伴瓣叶运动减低的HALT并不罕见但通常为亚临床;在有限病例中未额外抗凝治疗,瓣膜血流动力学及中期结局未见异常事件。
研究设计与样本
- 单中心注册研究,连续100例中研究70例植入Edwards SAPIEN-XT装置的患者,分析6个月和1年随访的多排CT、超声心动图及实验室数据。
关键影像表现/征象
- 多排CT显示瓣叶低密度增厚(HALT),出院时1例(1.4%)、6个月7例(10.0%)、1年累积10例(14.3%)。
- 基于10例患者数据,4维多排CT上瓣叶运动受限程度与HALT面积相关(r=0.68)。
- HALT组随访期D-二聚体升高:6个月2.3 μg/ml(IQR 2.1–6.1)vs 非HALT组1.1 μg/ml(IQR 0.8–2.2),p=0.002;1年2.7 μg/ml(IQR 1.7–4.8)vs 1.2 μg/ml(IQR 0.9–2.1),p=0.006;出院时无差异。
- HALT组1年随访压力梯度降低(8.3±0.8 mm Hg vs 11.1±4.9 mm Hg,p=0.005)。
诊断标准与关键数值
- HALT与男性相关:HALT组70% vs 非HALT组25%(p=0.008)。
- HALT与较大主动脉窦相关:31.0±2.0 mm vs 28.6±2.6 mm(p=0.005)。
- HALT与生物瓣尺寸相关:26 mm瓣7/21(33.3%)vs 23 mm瓣3/49(6.1%),p=0.006。
临床应用与阅片要点
- TAVR术后多排CT可检出HALT,常伴瓣叶运动减低,但多为亚临床。
- 男性、较大主动脉窦及较大生物瓣尺寸的患者HALT发生率较高。
- 发现HALT后未额外抗凝治疗,本组病例瓣膜血流动力学及中期结局未见异常事件。
局限性
- 单中心注册研究。
- 病例数有限(70例)。
- 作者结论称在有限病例中未额外抗凝治疗结局未见异常事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study sought to clarify the incidence and predictors of hypoattenuated leaflet thickening (HALT) and mid-term outcomes after transcatheter aortic valve replacement.
BACKGROUND: HALT detected on multidetector computed tomography (MDCT) scanning raised concerns about possible subclinical leaflet thrombosis.
METHODS: We studied 70 of 100 consecutive patients from a single-center registry who underwent implantation with the Edwards SAPIEN-XT device. MDCT results, echocardiographic data, and laboratory findings obtained at the 6-month and 1-year follow-ups were analyzed.
RESULTS: Of 70 patients, MDCT scans revealed HALT in 1 patient (1.4%) at discharge, 7 (10.0%) at 6 months, and 10 (14.3%) at 1 year post-transcatheter aortic valve replacement cumulatively. The degree of leaflet immobility correlated with the HALT area on 4-dimensional MDCT (r = 0.68) on the basis of data from 10 patients. HALT was associated with male sex (70% vs. 25%; p = 0.008) and larger sinus of Valsalva (31.0 ± 2.0 mm vs. 28.6 ± 2.6 mm; p = 0.005). HALT was found in 3 of 49 patients with a 23-mm bioprosthesis and in 7 of 21 patients with a 26-mm bioprosthesis (6.1% vs. 33.3%; p = 0.006). D-dimer levels were significantly increased in the HALT group at the 6-month (2.3 μg/ml [interquartile range (IQR): 2.1 to 6.1 μg/ml] vs. 1.1 μg/ml [IQR: 0.8 to 2.2 μg/ml]; p = 0.002) and 1-year (2.7 μg/ml [IQR: 1.7 to 4.8 μg/ml] vs. 1.2 μg/ml [IQR: 0.9 to 2.1 μg/ml]; p = 0.006) follow-ups, despite no differences at discharge. The pressure gradient was decreased in the HALT group at the 1-year follow-up (8.3 ± 0.8 mm Hg vs. 11.1 ± 4.9 mm Hg; p = 0.005). After detecting HALT, additional anticoagulation therapy was not administered. Clinical outcomes, including all-cause mortality (0% vs. 1.7%; p = 1.00) and stroke (0% vs. 0%; p = 1.00), were similar between the groups.
CONCLUSIONS: HALT with reduced leaflet motion was not rare but usually subclinical. Valve hemodynamics and mid-term outcomes were uneventful even without additional anticoagulant therapy in our limited number of cases. Male sex, larger sinus and bioprosthesis size, and elevated D-dimer levels during follow-up were associated with this phenomenon.
引用
- Yanagisawa R, Hayashida K, Yamada Y, et al. Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR. JACC Cardiovasc Imaging. 2016. PMID: 28017712. doi:10.1016/j.jcmg.2016.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。